Johnson & Johnson, headquartered in New Brunswick, New Jersey, employs 131,900 people and focuses on healthcare through its Innovative Medicine and MedTech segments. Innovative Medicine targets various therapeutic areas, while MedTech offers products for orthopedic and cardiovascular interventions.
JNJ has been in the news recently: Johnson & Johnson's icotrokinra demonstrated significant effectiveness in Phase 3 trials for plaque psoriasis, with nearly 50% of patients achieving complete skin clearance. Additionally, in the Phase 2b ANTHEM-UC study for ulcerative colitis, icotrokinra reached clinical remission rates of 30.2% by Week 12.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
